Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box 591, SE-751 24, Uppsala, Sweden.
Pharm Res. 2012 Feb;29(2):574-84. doi: 10.1007/s11095-011-0595-2. Epub 2011 Sep 23.
To outline and test a new modeling approach for prospective predictions of absorption from newly developed modified release formulations based on in vivo studies of gastro intestinal (GI) transit, drug release and regional absorption for the investigational drug AZD0837.
This work was a natural extension to the companion article "A semi-mechanistic model to link in vitro and in vivo drug release for modified release formulations". The drug release model governed the amount of substance released in distinct GI regions over time. GI distribution of released drug substance, region specific rate and extent of absorption and the influence of food intake were estimated. The model was informed by magnetic marker monitoring data and data from an intubation study with local administration in colon.
Distinctly different absorption properties were characterized for different GI regions. Bioavailability over the gut-wall was estimated to be high in duodenum (70%) compared to the small intestine (25%). Colon was primarily characterized by a very slow rate of absorption.
The established model was largely successful in predicting plasma concentration following administration of three newly developed formulations for which no clinical data had been applied during model building.
概述并测试一种新的建模方法,用于根据新开发的改良释放制剂的体内研究,对研究药物 AZD0837 的吸收进行前瞻性预测,这些研究包括胃肠道 (GI) 转运、药物释放和局部吸收。
这项工作是对“将体外和体内药物释放与改良释放制剂相关联的半机理模型”这篇伴随文章的自然延伸。药物释放模型控制了随着时间的推移在不同 GI 区域中释放的物质数量。估计了释放药物物质在特定 GI 区域中的分布、区域特异性吸收速度和程度,以及食物摄入的影响。该模型由磁标记监测数据和在结肠局部给药的插管研究数据提供信息。
不同的 GI 区域表现出明显不同的吸收特性。与小肠 (25%) 相比,十二指肠的肠壁生物利用度估计较高(70%)。结肠的主要特征是吸收速度非常缓慢。
所建立的模型在预测三种新开发制剂的血浆浓度方面取得了很大成功,这些制剂在建立模型期间没有应用临床数据。